Fibrotic disorders are an increasing cause of morbidity and mortality worldwide contributing to approx. 45% of deaths in the developed world. A major cause of liver fibrosis is NASH, a severe form of the metabolic condition non-alcoholic fatty liver disease (NAFLD).
Prostate cancer (PC) is a common and multifocal disease, with symptoms ranging from harmless to lethal. In Sweden, about 10000 new cases are diagnosed every year.
Breast cancer, the most common cancer in women, needs improved drugs to increase patient survival. Our innovation, a small molecule that simultaneously affects two well-recognized cancer targets, the STAT3 protein and G-quadruplex (G4) DNA structures, will reduce drug-resistance and improve treatment.
Pro Test Diagnostics has developed a routine test to monitor and detect illegal use of one’s own stored blood to enhance performance in elite athletes. The ABT™-test can expose athletes who have used blood doping and the result is not affected by the athlete’s training intensity, the use of high-altitude training or the use of low oxygen tents.
We are developing an oral patch, with a pending patented galenic formulation, providing immediate pain relief. The product can theoretically reach a target patient population of 10-20,000 patients annually in Sweden, and considerably higher in international markets.
Quretech Bio develops innovative antibiotics by stopping bacterial virulence with a first-in-class active substance. The approach is not to kill bacteria, but make them harmless – thus complementing existing treatments and making established antibiotic drugs more effective without causing resistance.
MetaCurUm Biotech is developing a novel antibody treatment for metastatic cancers. The company´s drug development program is focused on transforming growth factor-beta (TGFβ) driven cancers, with the aim to optimize the treatment paradigms in aggressive forms of cancer with high unmet medical need such as prostate, lung, kidney, and endometrial cancer.
Acne vulgaris affects more than 80 percent of people at some point in their life and frequently continues into adulthood. Recent data suggest that there are about 680 million people living with acne around the world. This case focuses on a novel approach to fighting acne without the hazards of antibiotic resistance development.
We are developing safe and resistance-breaking molecules that target an enzyme essential for nerve signaling in mosquitoes via a new mode of action. In contrast to current insecticides, we have designed our molecules to specifically target mosquitoes, without affecting other organisms.
Hiloprobe AB has developed a superior method of diagnosing and prognosing patients with colorectal cancer after surgery. Their innovative clinical tool – the ColoNode is far more accurate than current standard procedures, opening up the possibility of personalized medicine within the colorectal cancer field.